Health TrialsbyHealthPanel

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

ConditionBaseline Thrombocytopenia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMethodist Health System

About this trial

The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

≥ 18 years

PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)

Thrombocytopenia defined as platelet count <100 x103 /µL on at least one occasion prior to PCI

At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor

Disqualifiers

Death within 48 hours post-PCI

DAPT prior to cardiac catheterization

Trial population

Study population of 18 years of age ,PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021) ,Thrombocytopenia on at least one occasion prior to PCI and at least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor

Trial design

Design model

Other

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Incidence of bleeding

To evaluate the difference in bleeding rates in patients with chronic thrombocytopenia maintained on DAPT with clopidogrel compared to patients maintained on DAPT with ticagrelor.

Time frame
1 year

Secondary outcomes

1

Incidence of ischemic events

number of ischemic events

Time frame
1 year
2

All-cause mortality

all-cause mortality in patients with chronic thrombocytopenia maintained on DAPT with clopidogrel compared to patients maintained on DAPT with ticagrelor.

Time frame
1 year
3

Duration of DAPT

To evaluate the difference in rate of ischemic events and all-cause mortality in patients with chronic thrombocytopenia maintained on DAPT with clopidogrel compared to patients maintained on DAPT with ticagrelor.

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Methodist Health System

Lead sponsor

Source ClinicalTrials.gov
Apply now